This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    News
    20/12/21

    MHRA (UK) approves Tukysa for the treatment of advanced HER2-positive breast cancer.- Seagen

    The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tukysa (tucatinib + trastuzumab + capecitabine), from Seagen, for the treatment of advanced HER2-positive breast cancer.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    18/06/17

    NICE in final guidance recommendsroutine use of Kadcyla (ado-trastuzumab emtansine) for women with advanced and inoperable HER2-positive breast cancer.- Roche

    The National Institute of Health and Care Excellence (NICE) in a final decision recommended routine use of Kadcyla (ado-trastuzumab emtansine)...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/12/23

    Tukysa (tucatinib) in combination with antibody-drug conjugate ado-trastuzumab emtansine improves progression-free survival in previously treated HER2-positive metastatic breast cancer

    Seagen Inc. announced data from the Phase III HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla)

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    11/10/19

    Seattle Genetics initiates phase III trial ( HER2CLIMB-02) of tucatinib + ado-trastuzumab emtansine to treat metastatic HER2-positive (HER2+) breast cancer.

    Seattle Genetics, Inc. announced dosing of the first patient in HER2CLIMB-02, a randomized phase III clinical trial evaluating investigational agent...

    News
    20/12/21

    EMA validates MAA for tucatinib, + trastuzumab + capecitabine, to treat locally advanced unresectable or metastatic HER2-positive breast cancer, including brain metastases. Seattle Genetics

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/12/21

    Australia joins U.S., Switzerland, Canada and Singapore in approval of Tukysa for the treatment of patients with locally advanced or metastatic HER2-positive breast cancer - Seattle Genetics

    Seattle Genetics, Inc.has announced that Australian regulatory authorities have approved Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    06/02/20

    EMA validates MAA for tucatinib, + trastuzumab + capecitabine, to treat locally advanced unresectable or metastatic HER2-positive breast cancer, including brain metastases. Seattle Genetics

    Seattle Genetics, Inc.has announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/08/14

    NICE rejects Kadcyla as too expensive for HER2 positive Breast Cancer - Roche

    The National Institute for Health and Care Excellence (NICE) in draft guidance has rejected Kadcyla (trastuzumab emtansine) or T-DM1, from...

    A close up image of a microscope
    Clinical trial
    02/04/13

    A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

    This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in...

    • Source: Clinicaltrials.gov
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/04/22

    NICE recommends tucatinib + trastuzumab + capecitabine to treat HER-2 positive breast cancer.- Seagen

    National Institute for Health and Care Excellence (NICE) recommends;Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies Technology appraisal guidance [TA786]Published: 27 April 2022.

    See more